Senior insider sale
Chief Development Officer at SYROS PHARMACEUTICALS, INC. — senior position signals high conviction
$20.7K
42.24K shares
What this filing means
STEPHENS KRISTIN plans to sell 42.24K shares of SYROS PHARMACEUTICALS, INC. valued at approximately $20.7K. Form 144 is a notice of intent to sell restricted or control securities — not a mandatory transaction. This filing provides advance warning of potential selling pressure.
Filed: 11/18/2024ACC: 0001972362-24-001669
Officer· Chief Development Officer
Since Jun 2021
42.24K
Shares to sell
$20.7K
Approx. market value
36.13K
Acquired (3 months)
1
Planned
1 completed
Securities Acquired — Last 3 Months5
RESTRICTED STOCK
COMPENSATION
10/31/2024
10.90KRESTRICTED STOCK
COMPENSATION
3/31/2024
9.45KRESTRICTED STOCK
COMPENSATION
10/31/2023
11.32KRESTRICTED STOCK
COMPENSATION
3/31/2023
1.38KRESTRICTED STOCK
COMPENSATION
3/31/2022
3.09KTotal acquired36.13K
| Acquisition Date | Type | Amount Acquired | Gift |
|---|---|---|---|
10/31/2024 | RESTRICTED STOCK COMPENSATION | 10.90K | — |
3/31/2024 | RESTRICTED STOCK COMPENSATION | 9.45K | — |
10/31/2023 | RESTRICTED STOCK COMPENSATION | 11.32K | — |
3/31/2023 | RESTRICTED STOCK COMPENSATION | 1.38K | — |
3/31/2022 | RESTRICTED STOCK COMPENSATION | 3.09K | — |
| Total | 36.13K | ||
Planned & Completed Dispositions2
Completed
—Completed
Units to sell
6.10K
Market value
$12.7K
11/1/2024
Planned — Approximate Date
NASDAQPlanned
Units to sell
36.13K
Market value
$7.9K
11/18/2024
Total
Units
42.24K
Value
$20.7K
| Date | Units to Sell | Approx. Market Value | Exchange | Status |
|---|---|---|---|---|
| Completed | ||||
11/1/2024 | 6.10K | $12.7K | — | Completed |
| Planned — Approximate Date | ||||
11/18/2024 | 36.13K | $7.9K | NASDAQ | Planned |
| Total | 42.24K | $20.7K | ||